FILE:JNJ/JNJ-8K-20080912144006.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
 
 
 
Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On September 12, 2008, the Company announced that Christine A. Poon, 56, Vice Chairman of the Board of Directors and Worldwide Chairman, Pharmaceuticals Group, has announced plans to retire on March 1, 2009 from the Company and the Board.  Ms. Poon began her career with the Company in 2000 and was elected to the Companys Board of Directors and named a Vice Chairman of the Board in 2005.  The related press release dated September 12, 2008 is attached as Exhibit 99.1 to this Report.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
                                
Exhibit No.
Description
99.1                                Press release dated September 12, 2008

Exhibit 99.1
Press Contact:                      Jeffrey J. Leebaw
732-524-3350
Investor Contacts:               Louise Mehrotra                                Stan Panasewicz
732-524-6491                                       732-524-2524
FOR IMMEDIATE RELEASE
New Brunswick, NJ (September 12, 2008) - -- Johnson & Johnson said today that Christine A. Poon, 56, Vice Chairman of the Board of Directors and Worldwide Chairman, Pharmaceuticals Group, has announced plans to retire on March 1, 2009, from the Company and the Board, after more than 23 years in the health care industry and eight years with the Company.
 
William C. Weldon, Chairman and CEO, said, "Chris has been instrumental in helping to build Johnson & Johnson's pipeline of medicines to its place today as one of the worlds most highly-regarded.  We will certainly miss Chris' counsel, her leadership focus in building our pharmaceuticals business and her constant quest to bring better health and well-being to people around the world.  She has exhibited strong leadership and personal involvement in building a skilled and diverse workforce.  As a member of our Executive Committee and Vice Chairman, Chris has helped to shape Johnson & Johnsons strategy and vision for the future."
 
Ms. Poon began her career with Johnson & Johnson in November, 2000, as Company Group Chairman, Pharmaceuticals.  In August, 2001, she was promoted to the Executive Committee and named Worldwide Chairman, Pharmaceuticals.  Ms. Poon was appointed Worldwide Chairman, Medicines & Nutritionals, in October 2003.  She was elected to the Johnson & Johnson Board of Directors and named a Vice Chairman of the Board in 2005.  Prior to joining Johnson & Johnson, Ms. Poon spent 15 years at Bristol-Myers Squibb, where her most recent position was President of International Medicines.  Ms. Poon is on the Board of Directors of Prudential Financial, Inc., in Newark, NJ, and the Fox Chase Cancer Center in Philadelphia, PA.
 
Mr. Weldon said a timely announcement of pharmaceutical succession plans will be made to ensure a smooth transition of Ms. Poons Pharmaceuticals Group responsibilities.
About Johnson & Johnson
Caring for the world, one person at a timeinspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 120,200 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.


